Multiple sclerosis drug prices international comparison to US 2018

Although there was variation in price between select multiple sclerosis drugs, in all cases the U.S. price per dose was higher than the average of the 11 other countries in this analysis. Avonex, was over 1,400 U.S. dollars more expensive in the U.S. compared to the non-U.S. average price.

Price comparison U.S. vs. international per dose for select multiple sclerosis drugs in 2018* (in U.S. dollars)

Characteristic	U.S. price	Average (excluding U.S.) price
Avonex Pen	1,697.49	270.95
Avonex	1,697.49	252.74
Tecfidera	122.77	22.61
Rebif	606.67	177.05
Gilenya	261.9	66.28
Aubagio	233.18	36.94

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

September 2019

More information

Region

Worldwide

Survey time period

2018

Supplementary notes

* Based on price data for 2018, collected from recognized price sources. Countries included in analysis: United States, United Kingdom, Japan, Canada, Australia, Portugal, France, Netherlands, Germany, Denmark, Sweden, Switzerland. Comparison is with U.S. drug prices under Medicare Part D. Information on types of Multiple Sclerosis medication provided by National Multiple Sclerosis Society.

Citation formats